摘要
There is no robust genomic signature to predict the prognosis of patients with early-stage lung adenocarcinoma (LUAD). It was known that clonal heterogeneity was closely associated to tumour progression and prognosis prediction. Herein, using stage I patients from The Cancer Genome Atlas, we identified the clonal/subclonal events of each gene and preselected a set of genes with prognosis-specific mutation patterns based on a robust published transcriptomic prognostic signature. Subsequently, we constructed a mutational prognostic signature (MPS), whose prognostic performance was independently validated in two datasets of stage I samples. The predicted high-risk patients had significantly higher immune cell infiltration, along with higher expression of cytotoxic and immune checkpoint genes, and an integrated dataset with 88 samples confirmed that high-risk patients could benefit from immunotherapy. The developed MPS can identify the high-risk patients with stage I LUAD and improve individualised treatment planning of high-risk patients who might benefit from immunotherapy. Key messages We creatively developed a prognostic signature (57-MPS) based on clonal diversity. The high-risk samples displayed an underlying immunosuppressive mechanism. 57-MPS improved the predictive performance of PD-L1 for immunotherapy.
学科与关键词
- Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Wu, Chengde; Rao, Xiang; Lin, WeiCancer Med, 2021, 10(3): 806-823.
- Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
- Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell CarcinomaLi, Na; Wang, Jiahong; Zhan, Xianquan*Frontiers in Immunology, 2021, 12: 752643.被引 19
